Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab)

Thursday, October 5, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

- Praluent continues to be available to patients in the U.S. -

Contact Regeneron:

Media Relations

Arleen Goldenberg

Tel: + 1 (914) 847-3456

Mobile: +1 (914) 260-8788

[email protected]

Investor Relations Manisha Narasimhan, Ph.D. Tel.: +1 (914) 847-5126

[email protected]

 



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook